Xenofon Sakellariou

Dr. Xenofon Sakellariou

1st Cardiology Department, University Hospital of Ioannina, Greece
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
GPGeorgios Evaggelos Papadopoulos
Georgios Evaggelos Papadopoulos
Foteini BalomenouFoteini Balomenou
Foteini Balomenou
XSXenofon Sakellariou
Xenofon Sakellariou
CTChristos Tassopoulos
Christos Tassopoulos
DNDimitrios N. Nikas
Dimitrios N. Nikas
Theofilos KolettisTheofilos Kolettis
Theofilos Kolettis
Background: Obesity is invariably accompanied by autonomic dysfunction, although data in pediatric populations are conflicting. Methods: We conducted a systematic review and meta-analysis of 12 studies (totaling 1102 participants) comparing obese and normal-weight subjects (5–18 years of age), defined as body mass index >95th or <85th percentile, respectively. Using a random-effects model, we report the standardized mean differences (SMD) of sympathetic and vagal indices of heart rate variability. Results: Autonomic dysfunction was present in the obesity group, based on the average SMD in the standard deviation of sinus intervals (at −0.5340), and on the ratio of low (LF)- to high (HF)-frequency spectra (at 0.5735). There was no difference in sympathetic activity, but the heterogeneity among the relevant studies weakens this result. SMD in HF (at 0.5876), in the root mean square of successive differences between intervals (at −0.6333), and in the number of times successive intervals exceeded 50 ms divided by the total number of intervals (at −0.5867) indicated lower vagal activity in the obesity group. Conclusions: Autonomic dysfunction is present in obese children and adolescents, attributed to lower vagal activity. Further studies are needed in various pediatric cohorts, placing emphasis on sympathetic activity.

24 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DNDimitrios N. Nikas
Dimitrios N. Nikas
LLLampros Lakkas
Lampros Lakkas
SNSotirios Nikopoulos
Sotirios Nikopoulos
KTKonstantinos I Tsamis
Konstantinos I Tsamis
XSXenofon Sakellariou
Xenofon Sakellariou
LMLampros Michalis
Lampros Michalis
Transcatheter Aortic Valve Implantation (TAVI) has revolutionized the treatment of severe aortic stenosis in high-risk and inoperable patients. Despite significant advancements in patient selection, techniques, and the evolution of TAVI devices, stroke persists as a consistent adverse event over time, presenting a devastating complication of TAVI procedures and exerting a significant negative prognostic impact. Both acute and subsequent strokes following TAVI continue to pose significant challenges, with substantial implications for patient morbidity and mortality. This paper reviews the incidence, mechanisms, risk factors, and preventive strategies for stroke in TAVI, highlighting recent advancements, particularly in current protective devices, and ongoing challenges in minimizing this adverse outcome.

14 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EMEleftheria M. Mastoridou
Eleftheria M. Mastoridou
FFFotios S. Fousekis
Fotios S. Fousekis
XSXenofon Sakellariou
Xenofon Sakellariou
KMKonstantinos Mpakogiannis
Konstantinos Mpakogiannis
DNDimitrios N. Nikas
Dimitrios N. Nikas
HMHaralampos Milionis
Haralampos Milionis
Background/Objectives: Ιnflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative colitis (UC), is increasingly associated with cardiovascular (CV) complications, such as heart failure (HF), arrhythmias, and acute coronary syndromes (ACSs). As the therapeutic landscape of IBD evolves, with the introduction of newer biologics and small molecules, their CV safety warrants critical evaluation. The objective of this review is to provide an update on the current evidence of CV risks associated with IBD treatments. Methods: A comprehensive literature search from inception to April 2025 was conducted using PubMed and Medline to identify randomized controlled trials, observational studies, systematic reviews, as well as pharmacovigilance data reporting CV safety outcomes of biologic and small-molecule drugs approved for IBD. Additionally, analysis of the European Summary of Product Characteristics for each agent was also performed. Results: Anti-TNF agents, particularly infliximab, have been associated with increased reporting of HF and arrhythmias, particularly in patients with pre-existing cardiac disease. Ustekinumab and vedolizumab show consistently favorable CV safety profiles across trials and real-world studies. IL-23p19 inhibitors demonstrate low CV event rates overall, although signals for atrial fibrillation have emerged with risankizumab. Janus kinase inhibitors and sphingosine-1-phosphate receptor modulators carry class-specific CV warnings, due to signals mainly on non-IBD populations, and require careful use in high-risk individuals. Conclusions: Although most IBD therapies are generally safe from a CV perspective, certain agents may pose risks in vulnerable patients. Individualized CV risk assessment and ongoing post-marketing surveillance are essential to guide therapeutic choices and ensure patient safety.

17 December 2023 in Cardiovascular Revascularization Medicine
Verified
Journal Article
Closed access
XSXenofon Sakellariou
Xenofon Sakellariou
CKChristos S. Katsouras
Christos S. Katsouras
MPMichail I. Papafaklis
Michail I. Papafaklis
CFChristos Floros
Christos Floros
LMLampros K. Michalis
Lampros K. Michalis
DKDimitri Karmpaliotis
Dimitri Karmpaliotis

26 July 2025 in World Journal of Cardiology
Verified
Journal Article
Open access
XSXenofon Sakellariou
Xenofon Sakellariou
DNDimitrios Ν Nikas
Dimitrios Ν Nikas
PPPanagiotis Papanagiotou
Panagiotis Papanagiotou
ELEvangelos Liberopoulos
Evangelos Liberopoulos
MFMatilda Florentin
Matilda Florentin
TKTheofilos M Kolettis
Theofilos M Kolettis
Transradial access (TRA) has emerged as the preferred vascular access route for coronary angiography and percutaneous coronary interventions due to its superior safety profile compared to transfemoral access. However, its widespread adoption raises concerns regarding structural alterations in the radial artery, which may impact long-term vascular health and future procedural feasibility. TRA is associated with histopathologic changes in the arterial wall, such as intimal injury and hyperplasia, medial remodeling and adventitial inflammation, collectively contributing to radial artery remodeling. Moreover, TRA can induce changes in radial artery lumen diameter driven by an inflammatory response due to arterial puncture and mechanical friction during the procedure. Nonetheless, a more clinically significant consequence is radial artery occlusion, which is influenced by various procedural and patient-related factors. Strategies to minimize remodeling include meticulous pre-procedural ultrasound assessment to ensure appropriate sheath-to-artery size matching, periprocedural pharmacological interventions and implementation of patent hemostasis techniques. This review synthesizes current knowledge regarding the mechanisms, clinical implications, and preventive strategies related to radial artery remodeling following TRA. Further research is needed to elucidate the long-term consequences of radial artery remodeling and to refine preventive strategies for preserving radial artery patency and its suitability for future interventions.

XSXenofon Sakellariou
Xenofon Sakellariou
GKGeorgios I. Katsanos
Georgios I. Katsanos
AEAndreas P. Efstathopoulos
Andreas P. Efstathopoulos
DSDimitrios Sfairopoulos
Dimitrios Sfairopoulos
KSKonstantinos V. Stamatis
Konstantinos V. Stamatis
DNDimitrios N. Nikas
Dimitrios N. Nikas
Patients with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI) may demonstrate distal microvascular embolization of thrombotic materials. We retrospectively examined 20 cases displaying extensive thrombus in the infarct-related artery (IRA), treated either with a two-step procedure, with interim tirofiban infusion, or immediate stent implantation. Distal embolization tended to be more common in the latter strategy, but, overall, the outcome was comparable. Thus, a two-staged procedure may be considered in selected cases of primary PCI associated with high thrombus burden.